This preprint reports a feasibility study of a movement-responsive deep brain stimulation (mDBS) paradigm in four patients with Parkinson’s disease implanted with sensing-enabled DBS systems. The mDBS approach modulated stimulation of the subthalamic nucleus based on detection of volitional movement decoded from cortical activity, rather than maintaining a constant stimulation amplitude as in conventional therapy (cDBS). The authors obtained institutional review board approval from the University of California, San Francisco and referenced clinical trial registration NCT03582891.
During structured motor assessments, the movement-responsive stimulation paradigm produced measurable motor benefits compared with constant-amplitude stimulation. Specifically, mDBS increased average forearm speed across the tasks and mitigated the progressive bradykinetic slowing that was observed when patients were on cDBS. The reported improvement reflects an enhancement in motor performance that emerged while stimulation was dynamically linked to volitional motion decoded from cortex.
The source describes these task-based benefits as both immediate and cumulative over the course of the structured testing sessions. The abstract does not provide detailed numerical outcomes, effect sizes, or formal statistical metrics; those details are not reported in the source summary and would require inspection of the full manuscript or underlying data.
Motor improvements with mDBS were accompanied by neurophysiologic changes recorded from sensorimotor cortex. The authors observed a cumulative increase in sensorimotor cortical beta activity and in measures of cortical–subcortical connectivity during the sessions with movement-responsive stimulation. These findings suggest that adaptive stimulation tied to volitional movement may reinforce physiological patterns of motor circuit activity, rather than simply suppressing pathological signals.
The source indicates these neural changes developed over time during task performance alongside behavioral improvements. Exact recording parameters, connectivity metrics, and statistical tests are not provided in the abstract excerpt and are therefore not reproduced here.
Beyond structured tasks, the study evaluated mDBS during unconstrained, everyday activities. In that setting, mDBS lowered average bradykinesia severity relative to baseline or to cDBS. Importantly, the authors report a progressive reduction in symptoms over hours of continuous mDBS therapy, indicating a time-dependent accumulation of benefit during naturalistic use.
As with the task-based findings, the abstract does not include granular numeric data or patient-level trajectories. The statement is based on the aggregated observations reported in the source preprint.
The therapeutic gains observed during mDBS were not permanent: when the investigators switched participants back to constant-amplitude DBS, the progressive symptom reductions gradually reversed. This reversibility underscores the state-dependent and dynamic nature of the intervention, suggesting the sustained benefits require continued engagement of the movement-responsive strategy.
Comparisons reported in the abstract are limited to descriptions of behavioral and physiologic differences between mDBS and cDBS; detailed comparative statistics and long-term outcome data were not included in the source abstract.
The authors confirm adherence to relevant ethical guidelines and IRB approval from the University of California, San Francisco. They state that all necessary participant consents were obtained. De-identified processed data and relevant code used for figures and analyses can be made available on request, subject to institutional and regulatory requirements.
Competing interests and funding relationships are disclosed in the source. Specific declarations include industry funding and consulting relationships for some authors, a patent related to daytime decoding of movement for adaptive DBS, and funding support identified as a Weill NeuroHub Investigators Award. The abstract does not report device-specific adverse events or a formal safety profile; those details would need to be verified in the full manuscript.
These initial results support the feasibility of a cortical-decoded, movement-responsive DBS approach that dynamically modulates subthalamic stimulation to strengthen motor circuit function in Parkinson’s disease. The reported behavioral improvements, accompanied by increases in sensorimotor cortical beta activity and connectivity, are consistent with a mechanism in which adaptive, movement-linked stimulation reinforces functional motor networks.
Because the present report summarizes outcomes from four patients and provides limited numeric detail in the abstract, larger studies with pre-specified endpoints, transparent statistical reporting, and systematic safety assessment will be needed to determine clinical efficacy, optimal decoding and stimulation parameters, durability of benefit, and generalizability. The authors note availability of data and code on request, which could support further independent evaluation.